AXDX Accelerate Diagnostics
- 0.9419
- +0.0066+0.71%
- 0.9199
- -0.0220-2.34%
Accelerate Diagnostics News
Will Accelerate Diagnostics (AXDX) Report Negative Q1 Earnings? What You Should Know
Accelerate Diagnostics Scheduled Call to Review 2024 First Quarter Results.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Wednesday, May 8, 2024, at 4:30 p.m....
Texas Biomed Researching Vaccines and Treatments for Highly Pathogenic Avian Influenza
SAN ANTONIO, April 18, 2024 /PRNewswire/ -- Researchers at Texas Biomedical Research Institute (Texas Biomed) are studying potential vaccines, antivirals and antibodies against highly pathogenic avia
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q4 2023 Earnings Call Transcript
Accelerate Diagnostics Is Maintained at Hold by Craig-Hallum
Accelerate Diagnostics Is Maintained at Hold by Craig-Hallum
Craig-Hallum Maintains Hold on Accelerate Diagnostics, Lowers Price Target to $1
Craig-Hallum analyst Alexander Nowak maintains Accelerate Diagnostics (NASDAQ:AXDX) with a Hold and lowers the price target from $2 to $1.
Accelerate Diagnostics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 6.29% Craig-Hallum $2 → $1 Maintains Hold 03/09/2022 431.46% Craig-Hallum → $5 Downgrades Buy →
Analysts Have Conflicting Sentiments on These Healthcare Companies: Staar Surgical (STAA), DarioHealth (DRIO) and Accelerate Diagnostics (AXDX)
Stockholders Beware: Accelerate Diagnostics' Surge in Authorized Shares Signals Potential Dilution Risk
Q4 2023 Accelerate Diagnostics Inc Earnings Call
Earnings Call Summary | Accelerate Diagnostics(AXDX.US) Q4 2023 Earnings Conference
The following is a summary of the Accelerate Diagnostics Inc. (AXDX) Q4 2023 Earnings Call Transcript:Financial Performance:Accelerate Diagnostics reported Q4 net sales of approximately $3 million and
Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates
Accelerate Diagnostics GAAP EPS of -$0.89 Misses by $0.27, Revenue of $3M Misses by $0.45M
Accelerate Diagnostics 4Q R&D Expenses $5.6M >AXDX
Accelerate Diagnostics 4Q R&D Expenses $5.6M >AXDX
Accelerate Diagnostics 4Q Sales $3M >AXDX
Accelerate Diagnostics 4Q Sales $3M >AXDX
Accelerate Diagnostics 4Q Loss/Shr 89c >AXDX
Accelerate Diagnostics 4Q Loss/Shr 89c >AXDX
Press Release: Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results PR Newswire TUCSON, Ariz., March 28, 2024 TUCSON, Ariz., March 28, 2024 /PRNewswire/ -- Accelerate Diagnostics, In
Earnings Scheduled For March 28, 2024
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million. • Shimmick (NASDAQ:SHIM) is estimated
A Preview Of Accelerate Diagnostics's Earnings
Accelerate Diagnostics (NASDAQ:AXDX) is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Here's what investors need to know before the announcement.Analysts estimate that Acce
Earnings Week Ahead: Walgreens Boots Alliance, Carnival, GameStop and More
Analysis
Price Target
No Data
